Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $3.7 million.

  • TScan Therapeutics' Prepaid Assets rose 2519.39% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 2519.39%. This contributed to the annual value of $2.6 million for FY2024, which is 1910.62% up from last year.
  • Latest data reveals that TScan Therapeutics reported Prepaid Assets of $3.7 million as of Q3 2025, which was up 2519.39% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Prepaid Assets ranged from a high of $5.3 million in Q1 2023 and a low of $1.4 million during Q2 2023
  • In the last 5 years, TScan Therapeutics' Prepaid Assets had a median value of $3.4 million in 2025 and averaged $3.3 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 15689.24% in 2021, then plummeted by 6342.71% in 2024.
  • TScan Therapeutics' Prepaid Assets (Quarter) stood at $4.2 million in 2021, then decreased by 3.51% to $4.1 million in 2022, then crashed by 46.51% to $2.2 million in 2023, then grew by 19.11% to $2.6 million in 2024, then soared by 42.11% to $3.7 million in 2025.
  • Its Prepaid Assets stands at $3.7 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.